Refining the treatment of NSCLC according to histological and molecular subtypes

Nature Reviews Clinical Oncology

Volumn 12, Issue 9, 2015, Pages 511-526

  Thomas, Anish ^a   Liu, Stephen V ^b   Subramaniam, Deepa S ^b   Giaccone, Giuseppe ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CERITINIB; CETUXIMAB; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; NECITUMUMAB; NEW DRUG; NIVOLUMAB; OSIMERTINIB; PACLITAXEL; PROTEIN RET; RAMUCIRUMAB; ROCILETINIB; ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE; TUMOR MARKER;

ALK GENE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CENTRAL NERVOUS SYSTEM DISEASE; DRUG EFFICACY; DRUG TARGETING; EGFR GENE; ENZYME INHIBITION; FUNCTIONAL ASSESSMENT; GENE; GENE MUTATION; GENETIC SCREENING; GENOMICS; GENOTYPE; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; RET GENE; REVIEW; ROS1 GENE; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; IMMUNOTHERAPY; LUNG NEOPLASMS; PERSONALIZED MEDICINE; PROTO ONCOGENE;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; GENES, ERBB-1; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PRECISION MEDICINE; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84940462680     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.90     Document Type: Review

References (118)

1. Ferlay J., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893-2917 (2010
2. Siegel R. L., Miller K. D., & Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 65, 5-29 (2015
3. Molina J. R., Yang P., Cassivi S. D., Schild S. E., & Adjei A. A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83, 584-594 (2008
4. [No authors listed] Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised Clinical.Trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311, 899-909 (1995
5. Green R. A., Humphrey E., Close H., & Patno M. E. Alkylating agents in bronchogenic carcinoma. Am. J. Med. 46, 516-525 (1969
6. Schiller J. H., et al. Comparison of four chemotherapy regimens for advanced non small cell lung cancer. N. Engl. J. Med. 346, 92-98 (2002
7. Johnson D. H., & Einhorn L. H. Paclitaxel plus carboplatin: an effective combination chemotherapy for advanced non small cell lung-cancer or just another Elvis sighting. J. Clin. Oncol. 13, 1840-1842 (1995
8. Levine B., & Weisberger A. S. Response of various types of bronchogenic carcinoma to nitrogen mustard. Ann. Intern. Med. 42, 1089-1096 (1955
9. Lynch T. J., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004
10. Paez J. G., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004
11. Scagliotti G. V., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non small cell lung cancer. J. Clin. Oncol. 26, 3543-3551 (2008
12. Sequist L. V., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31, 3327-3334 (2013
13. Rosell R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non small cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13, 239-246 (2012
14. Zhou C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non small cell lung cancer (OPTIMAL, CTONG 0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12, 735-742 (2011
15. Solomon B. J., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 371, 2167-2177 (2014
16. Camidge D. R., Pao W., & Sequist L. V. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat. Rev. Clin. Oncol. 11, 473-481 (2014
17. Oxnard G. R., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin. Cancer Res. 17, 1616-1622 (2011
18. Katayama R., et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 4, 120ra17 (2012
19. Park K. S., et al. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. J. Clin. Invest. 124, 3003-3015 (2014
20. Chong C. R., & Janne P. A. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat. Med. 19, 1389-1400 (2013
21. Lovly C. M., et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat. Med. 20, 1027-1034 (2014
22. Crystal A. S., et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480-1486 (2014
23. De Bruin E. C., et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251-256 (2014
24. Kobayashi S., et al. EGFR mutation and resistance of non small cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792 (2005
25. Pao W., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, 225-235 (2005
26. Engelman J. A., et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 67, 11924-11932 (2007
27. Li D., et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27, 4702-4711 (2008
28. Ramalingam S. S., et al. Randomized phase II study of dacomitinib (PF 00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non small cell lung cancer. J. Clin. Oncol. 30, 3337-3344 (2012
29. Katakami N., et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non small cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J. Clin. Oncol. 31, 3335-3341 (2013
30. Kim Y., et al. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol. Cancer Ther. 11, 784-791 (2012
31. Janne P. A., et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 32 (5s Suppl.), a8009 (2014
32. US National Library of Medicine. Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT02151981 (2015
33. Sequist L. V., et al. First in human evaluation of CO 1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M) [abstract]. J. Clin. Oncol. 32 (5s Suppl.), a8010 (2014
34. US National Library of Medicine. Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT02186301?term=NCT02186301&rank=1 (2015
35. Janjigian Y. Y., et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov. 4, 1036-1045 (2014
36. Janjigian Y. Y., et al. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin. Cancer Res. 17, 2521-2527 (2011
37. Seto T., et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non small cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 15, 1236-1244 (2014
38. Wu Y. L., et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non small cell lung cancer (FASTACT 2): a randomised, double-blind trial. Lancet Oncol. 14, 777-786 (2013
39. Mok T. S., et al. Gefitinib/chemotherapy vs chemotherapy in epidermal growth factor receptor (EGFR) mutation-positive non small cell lung cancer (NSCLC) after progression on first-line gefitinib: the phase III, randomised IMPRESS study [abstract]. Ann. Oncol. 25 (Suppl. 5), LBA2 PR (2014
40. Shaw A. T., et al. Ceritinib in ALK-rearranged non small cell lung cancer. N. Engl. J. Med. 370, 1189-1197 (2014
41. Friboulet L., et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 4, 662-673 (2014
42. Khozin S., et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin. Cancer Res. http://dx.doi.org/10.1158/1078-0432.CCR-14-3157 (2015
43. Gadgeel S. M., et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non small cell lung cancer (AF 002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 15, 1119-1128 (2014
44. US National Library of Medicine. Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT02075840 (2015
45. US National Library of Medicine. Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT02048488 (2015
46. US National Library of Medicine. Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT01625234 (2014
47. US National Library of Medicine. Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT01449461 (2014
48. Katayama R., et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin. Cancer Res. 20, 5686-5696 (2014
49. Sang J., et al. Targeted inhibition of the molecular chaperone HSP90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov. 3, 430-443 (2013
50. Socinski M. A., et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin. Cancer Res. 19, 3068-3077 (2013
51. US National Library of Medicine. Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT01579994 (2015
52. US National Library of Medicine. Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT01772797 (2014
53. Shaw A. T., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385-2394 (2013
54. US National Library of Medicine. Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT02134912 (2015
55. Ou S. H., et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK positive NSCLC. Ann. Oncol. 25, 415-422 (2014
56. Marzec M., et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD L1, B7 H1). Proc. Natl Acad. Sci. USA 105, 20852-20857 (2008
57. Pfizer. Pfizer And Merck To Collaborate On Study Evaluating Novel Anti-Cancer Combination Regimen [online], http://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-merck-to-collaborate-on-study-evaluating-novel-anti-cancer-combination-regimen (2014
58. Bearz A., et al. Activity of pemetrexed on brain metastases from non-small cell lung cancer. Lung Cancer 68, 264-268 (2010
59. Gerber N. K., et al. Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma. Int. J. Radiat. Oncol. Biol. Phys. 89, 322-329 (2014
60. Heon S., et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 16, 5873-5882 (2010
61. Ohashi K., Maruvka Y. E., Michor F., & Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J. Clin. Oncol. 31, 1070-1080 (2013
62. Grommes C., et al. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 13, 1364-1369 (2011
63. Sperduto P. W., et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int. J. Radiat. Oncol. Biol. Phys. 85, 1312-1318 (2013
64. Costa D. B., et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J. Clin. Oncol. http://dx/doi.org/10.1200/JCO.2014.59.0539 (2015
65. Costa D. B., et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J. Clin. Oncol. 29, e443-e445 (2011
66. US National Library of Medicine. Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT02075840 (2015
67. Thomas A., & Hassan R. Immunotherapies for non small cell lung cancer and mesothelioma. Lancet Oncol. 13, e301-e310 (2012
68. Topalian S. L., et al. Safety, activity, and immune correlates of anti PD 1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012
69. Brahmer J. R., et al. Safety and activity of anti PD L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012
70. Herbst R. S., et al. Predictive correlates of response to the anti PD L1 antibody MPDL3280A in cancer patients. Nature 515, 3563-3567 (2014
71. OPDIVO (nivolumab) injection, for intravenous use package insert [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/125554lbl.pdf (Bristol Myers Squibb, 2014
72. US Food and Drug Administration. FDA expands approved use of Opdivo to treat lung cancer [online], http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436534.htm (2015
73. Gettinger S., & Herbst R. S. B7 H1/PD 1 blockade therapy in non-small cell lung cancer: current status and future direction. Cancer J. 20, 281-289 (2014
74. Snyder A., et al. Genetic basis for clinical response to CTLA 4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014
75. Akbay E. A., et al. Activation of the PD 1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 3, 1355-1363 (2013
76. Azuma K., et al. Association of PD L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann. Oncol. 25, 1935-1940 (2014
77. Oxnard G. R., Binder A., & Jänne P. A. New targetable oncogenes in non small cell lung cancer. J. Clin. Oncol. 31, 1097-1104 (2013
78. Blackhall F. H., et al. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J. Clin. Oncol. 32, 2780-2787 (2014
79. Kris M. G., et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311, 1998-2006 (2014
80. Ju Y. S., et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 22, 436-445 (2012
81. Wang R., et al. RET fusions define a unique molecular and clinicopathologic subtype of non small cell lung cancer. J. Clin. Oncol. 30, 4352-4359 (2012
82. Drilon A., et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 3, 630-635 (2013
83. Bergethon K., et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30, 863-870 (2012
84. Shaw A. T., et al. Crizotinib in ROS1-rearranged non small cell lung cancer. N. Engl. J. Med. 371, 1963-1971 (2014
85. Hammerman P. S., et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 1, 78-89 (2011
86. Weiss J., et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci. Transl. Med. 2, 62ra93 (2010
87. Spigel D., et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC [abstract]. J. Clin. Oncol. 29 (Suppl.), a7505 (2011
88. Mazieres J., et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J. Clin. Oncol. 31, 1997-2003 (2013
89. Thomas A., et al. From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. Ann. Oncol. 24, 577-585 (2013
90. Dienstmann R., et al. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann. Oncol. 25, 552-563 (2014
91. Sleijfer S., Bogaerts J., & Siu L. L. Designing transformative Clinical.Trials in the cancer genome era. J. Clin. Oncol. 31, 1834-1841 (2013
92. Lopez-Chavez A., et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker derived multi-arm, multi-histology phase II "basket" trial. J. Clin. Oncol. 33, 1000-1007 (2015
93. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012
94. Iyer G., et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 338, 221 (2012
95. Takebe N., et al. Biomarkers: exceptional responders-discovering predictive biomarkers. Nat. Rev. Clin. Oncol. 12, 132-134 (2015
96. Devesa S. S., Bray F., Vizcaino A. P., & Parkin D. M. International lung cancer trends by histologic type: male: female differences diminishing and adenocarcinoma rates rising. Int. J. Cancer 117, 294-299 (2005
97. Socinski M. A., et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non small cell lung cancer: final results of a phase III trial. J. Clin. Oncol. 30, 2055-2062 (2012
98. Johnson D. H., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non small cell lung cancer. J. Clin. Oncol. 22, 2184-2191 (2004
99. Garon E. B., et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non small cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384, 665-673 (2014
100. Pujol J. L., et al. Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer 83, 211-218 (2014
101. Thatcher N., et al. A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC 11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq NSCLC) [abstract]. J. Clin. Oncol. 32 (5s Suppl.), a8008 (2014
102. Lindeman N. I., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J. Mol. Diagn. 15, 415-553 (2013
103. Malik S. M., et al. Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer. J. Thorac. Oncol. 9, 1443-1448 (2014
104. Pignon J. P., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 26, 3552-3559 (2008
105. Friboulet L., et al. ERCC1 isoform expression and DNA repair in non small cell lung cancer. N. Engl. J. Med. 368, 1101-1110 (2013
106. Gu F., Wisnivesky J. P., Mhango G., & Strauss G. M. Carboplatin versus cisplatin-based adjuvant chemotherapy in elderly patients with stages IB, II, and IIIA non-small cell lung cancer in the community setting [abstract]. J. Clin. Oncol. 31 (Suppl.), a7533 (2013
107. Goss G. D., et al. Gefitinib versus placebo in completely resected non small cell lung cancer: results of the NCIC CTG BR19 study. J. Clin. Oncol. 31, 3320-3326 (2013
108. Thatcher N., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non small cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366, 1527-1537 (2005
109. Kelly K., et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non small cell lung cancer: SWOG S0023. J. Clin. Oncol. 26, 2450-2456 (2008
110. Kelly K., et al. A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results [abstract]. J. Clin. Oncol. 32 (5s Suppl.), a7501 (2014
111. US National Library of Medicine. Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT02194738 (2014
112. US National Library of Medicine. Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT02201992 (2014
113. US National Library of Medicine. Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT02193282 (2015
114. Mok T., et al. Treating patients with EGFR-sensitizing mutations: first line or second line-is there a difference?. J. Clin. Oncol. 31, 1081-1088 (2013
115. Jiang X., et al. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD L1 expression that is reversible by MEK and PI3K inhibition. Clin. Cancer Res. 19, 598-609 (2013
116. Deborah A., et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J. Clin. Invest. 123, 1371-1381 (2013
117. Gulley J. L., et al. Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr. Oncol. 18, e150-e157 (2011
118. Begley J., & Ribas A. Targeted therapies to improve tumor immunotherapy. Clin. Cancer Res. 14, 4385-4391 (2008